|Bid||288.47 x 900|
|Ask||288.48 x 800|
|Day's Range||287.86 - 293.39|
|52 Week Range||228.65 - 344.32|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||32.34|
|Earnings Date||Dec 5, 2019|
|Forward Dividend & Yield||0.06 (0.02%)|
|1y Target Est||345.17|
While Cooper Companies Inc (NYSE: COO ) should be able to sustain its revenue growth momentum, despite changes in the competitive landscape, its gross margin may come under pressure due to mix shift and ...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.
Today we'll evaluate The Cooper Companies, Inc. (NYSE:COO) to determine whether it could have potential as an...
How far off is The Cooper Companies, Inc. (NYSE:COO) from its intrinsic value? Using the most recent financial data...
Guidewire (GWRE) is benefiting from adoption of its InsurancePlatform suite of products. Also, its acquisition strategies aimed at strengthening InsurancePlatform, remain a key catalyst.
Cooper Cos. (COO) delivered earnings and revenue surprises of 2.22% and -1.10%, respectively, for the quarter ended July 2019. Do the numbers hold clues to what lies ahead for the stock?
PLEASANTON, Calif., Aug. 29, 2019 -- CooperCompanies (NYSE: COO) today announced financial results for the fiscal third quarter ended July 31, 2019. Revenue increased 3%.
Reflecting its continued business momentum and medical device leadership, CooperCompanies (COO) today introduced an updated corporate brand name, brand identity and new website at www.coopercos.com. CooperCompanies’ innovative portfolio of contact lenses and women’s health products are available in more than 100 countries. “Today’s announcement reflects the dynamic medical device company we’ve become and our incredible, life-changing products,” said President and CEO Albert White.
Zacks.com featured highlights include: Novavax, The Cooper Companies, Veeco Instruments and Maxar Technologies
Marvell's (MRVL) fiscal second-quarter results are likely to be hurt by a weak storage and networking business. However, the Cavium business is likely to be a key growth driver.
Workday's (WDAY) revenue growth continues to be driven by high demand for its HCM and financial management solutions. Also, its diversified product portfolio is a positive.